Articles tagged "Immunosuppression"

2018 American Transplant Congress
Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients
M. J. Barten,¹ S. W. Hirt,¹ J. Garbade,¹ C. Bara,¹ A. Doesch,¹ C. Knosalla,¹ C. Grinninger,¹ J. Stypmann,¹ C. Sieder,² M. Junge,² U. Schulz.¹
¹Mandela Study Group, Germany; ²Novartis, Pharma, Germany.
Purpose: The MANDELA study (NCT00862979) was designed to assess the benefit on renal function of either CNI-free or CNI-minimized EVR-based regimen after early conversion of…
2018 American Transplant Congress
Association of Tacrolimus Adherence and Discontinuation with Sepsis Risk among Kidney Transplant Recipients
J. Donnelly,¹ P. MacLennan,¹ R. Mannon,¹ R. Saran,² J. Baddley,¹ H. Wang,³ G. McGwin, Jr.,¹ P. Muntner.¹
¹University of Alabama at Birmingham, Birmingham, AL; ²University of Michigan, Ann Arbor, MI; ³University of Texas Health Science Center, Houston, TX.
OBJECTIVE: The association between post-transplant tacrolimus exposure and sepsis risk is currently unknown. We examined the associations of tacrolimus adherence and discontinuation with sepsis risk…
2018 American Transplant Congress
Human CD8⁺CD28^– Ts Cells Expanded by Common Gamma Chain (γc) Cytokines Keep Steady Allospecific Suppressive Capacity In Vivo
G. Liu,¹ F. Feng,¹ P. Zhu,¹ J. Liu,² Y. Liu,¹ Y. Yu.²
¹Department of Immunology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China; ²Department of Urology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Background: CD8+CD28- T suppressor (Ts) cells were recently reported to play a critical role in transplant tolerance, harnessing the potential for clinical use in transplantation.…
2018 American Transplant Congress
Risk of Bacteremia According to Transplant Induction Immunosuppression Regimen
E. Misch, S. Kelley, G. Leverson, B. Astor, D. Kaufman.
University of Wisconsin School of Medicine and Public Health, Madison.
Background: Transplant immune suppression is designed to suppress the adaptive immune response and ensure graft survival, but may have unintended effects on innate immunity. Few…
2018 American Transplant Congress
Absence of Rejection in a Facial Allograft Recipient with a Postive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20+ Monoclonal Antibody
B. Gelb,¹ J. Diaz-Siso,² N. Plana,² A. Jacoby,² W. Rifkin,² K. Khouri,² D. Ceradini,² E. Rodriguez.²
¹Transplant Institute, NYU Langone Health, New York, NY; ²Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY.
OBJECTIVE: Vascularized composite allograft (VCA) transplantation has become a feasible reconstructive option for patients with severe facial disfigurement. Short term patient and graft survival have…
2018 American Transplant Congress
The Ratio of CTLA4 to Perforin and Granzyme B as a Potential Biomarker of Tolerance in Chimeric Renal Transplant Patients
A. Khalil,¹ A. Chhabra,¹ A. Merchak,¹ L. Kahn,¹ J. Leventhal,² S. Ildstad.¹
¹Institute for Cellular Therapeutics, University of Louisville, Louisville, KY; ²Northwestern University, Chicago, IL.
Background: Thirty-six subjects have been enrolled in a phase II clinical trial aimed to induce tolerance through chimerism. Each subject received FCRx (mPBMC enriched in…
2018 American Transplant Congress
Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
K. Tornatore,^1,4 K. Attwood,² D. Brazeau,³ S. Chang,⁴ R. Venuto.⁴
¹Pharmacy, School of Pharmacy, University at Buffalo(UB), Buffalo; ²Biostatistics, RPCI, Buffalo; ³Pharmaceutical Sciences, University of New England, Portland; ⁴Nephrology, UB School of Medicine, Buffalo.
Background: African American(AA) renal transplant recipients(RTR) require larger tacrolimus(TAC) doses to achieve similar troughs to Caucasians which may be due to CYP3A5 polymorphisms. TAC pharmacokinetics…
2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
M. Del Gaudio,¹ M. Cescon,¹ M. Ravaioli,¹ V. Bertuzzo,¹ C. Zanfi,¹ M. Serenari,¹ L. Maroni,¹ C. Morelli,² A. Pinna.¹
¹Organ Insufficiency and Transplantation, S.Orsola Hospital General Surgery and Transplantation Unit Prof. A.D. Pinna, Bologna, Italy; ²Organ Insufficiency and Transplantation, S. Orsola Hospital Organ Insufficiency and Internal Medicine Morelli, Bologna, Italy.
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…
2018 American Transplant Congress
Diagnosis and Prevalence of Strongyloidiasis in Solid Organ Transplant Patients
H. Pritchard,¹ V. Hemmige,¹ R. Mejia,² A. Restrepo.¹
¹Division of Infectious Diseases, Baylor College of Medicine, Houston, TX; ²National School of Tropical Medicine, Baylor College of Medicine, Houston, TX.
Background: Immunosuppression of a host with chronic Strongyloides stercoralis infection can lead to dissemination, with a fatality rate of up to 85%. Screening for S.…
2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
J. Assaker,¹ N. Murakami,¹ S. Eskandari,¹ M. Uehara,¹ C. Nathan,² H. Li,³ G. Lin,² J. Azzi.¹
¹Transplantation Renal Center, Harvard Medical School, Boston; ²Microbiology and Immunology, Weill Cornell Medicine, New York; ³Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…